✦ LIBER ✦

Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

✍ Scribed by Antonio Llombart-Cussac; Ángel Guerrero; Antonio Galán; Vicente Carañana; Elvira Buch; Álvaro Rodríguez-Lescure; Amparo Ruiz; Carlos Fuster Diana; Vicente Guillem Porta

Book ID: 113094810
Publisher: Springer Milan
Year: 2012
Tongue: Spanish
Weight: 355 KB
Volume: 14
Category: Article
ISSN: 1699-048X
DOI: 10.1007/s12094-012-0771-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial with letrozole (2.5 mg) t

Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

✍ A. Llombart; Galán; C. Fuster; E. Buch; V. Carañana; A. Rodriguez-Lescure; C. Vá 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 131 KB

P128 Phase II trial with letrozole (2.8

P128 Phase II trial with letrozole (2.8 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

✍ A. Lombart-Cussac; A. Galán; C. Fuster Diana; E. Buch; V. Carañana; A. Rodriguez 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

2044 POSTER Phase II trial with letrozol

2044 POSTER Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

✍ A. Llombart Cussac; A. Galán; C. Fuster; E. Buch; V. Carañana; A. Rodríguez Lesc 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Antitumour and biological effects of let

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer

✍ Torrisi, R; Bagnardi, V; Pruneri, G; Ghisini, R; Bottiglieri, L; Magni, E; Veron 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 146 KB

A Phase II trial of Zoladex combined wit

A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer

✍ Sheng Zhang, Chongjian Zhang, Jingjing Liu, Li Qin, Shude Cui, Jin Zhang 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 174 KB

Epirubicin plus cyclophosphamide vs. wee

Epirubicin plus cyclophosphamide vs. weekly paclitaxel as primary systemic therapy in patients with stage II and III breast cancer: randomized phase II study

✍ M. Miyashita; Kohno; S. Takao; K. Wakita; M. Konishi; H. Yoshimura; M. Kubota; Y 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 136 KB